Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 7:9:198.
doi: 10.3389/fneur.2018.00198. eCollection 2018.

Phase 1 Trial of Amnion Cell Therapy for Ischemic Stroke

Thanh G Phan  1 , Henry Ma  1 , Rebecca Lim  2 , Christopher G Sobey  3 , Euan M Wallace  2
Affiliations

Phase 1 Trial of Amnion Cell Therapy for Ischemic Stroke

Thanh G Phan et al. Front Neurol. .

Abstract

Background: There is increasing interest in stem cell therapy as another treatment modality in stroke, particularly for patients who are unable to receive endovascular clot retrieval or thrombolysis therapies, or for whom standard treatment has failed. We have recently shown that human amniotic epithelial cells (hAECs) are effective in reducing infarct volume in different animal models of ischemic stroke, including in non-human primates. hAEC therapy attenuated infarct growth and/or promoted functional recovery, even when administered 1-3 days after the onset of stroke.

Methods: We now propose an open label Phase 1 dose escalation trial to assess the safety of allogeneic hAECs in stroke patients with a view to providing an evidence platform for future Phase 2 efficacy trials. We propose a modified 3 + 3 dose escalation study design with additional components for measuring magnetic resonance signal of efficacy as well as the effect of hAECs on immunosuppression after stroke.

Result: The trial will commence in 2018. The findings will be published in a peer-reviewed journal.

Conclusion: The trial is registered with ANZCTR (ACTRN12618000076279p).

Keywords: amnion; phase 1; stem cell; stroke; trial.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Action of amnion stem cell on inflammatory cascade post ischemic stroke.
Figure 2
Figure 2
Schematics of dose escalation and de-escalation.
See this image and copyright information in PMC

References

    1. Saver JL, Goyal M, van der Lugt A, Menon BK, Majoie CB, Dippel DW, et al. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. JAMA (2016) 316:1279–88.10.1001/jama.2016.13647 - DOI - PubMed
    1. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med (2015) 372:1009–18.10.1056/NEJMoa1414792 - DOI - PubMed
    1. Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med (2017) 378:11–21.10.1056/NEJMoa1706442 - DOI - PubMed
    1. Ma H, Parsons MW, Christensen S, Campbell BC, Churilov L, Connelly A, et al. A multicentre, randomized, double-blinded, placebo-controlled phase iii study to investigate extending the time for thrombolysis in emergency neurological deficits (extend). Int J Stroke (2012) 7:74–80.10.1111/j.1747-4949.2011.00730.x - DOI - PubMed
    1. Lo EH. A new penumbra: transitioning from injury into repair after stroke. Nat Med (2008) 14:497–500.10.1038/nm1735 - DOI - PubMed